indacaterol: a beta2 adrenoceptor agonist; indacaterol is the (R)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
indacaterol : A monohydroxyquinoline that consists of 5-[(1R)-2-amino-1-hydroxyethyl]-8-hydroxyquinolin-2-one having a 5,6-diethylindan-2-yl group attached to the amino function. Used as the maleate salt for treatment of chronic obstructive pulmonary disease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 6918554 |
| CHEMBL ID | 1095777 |
| CHEBI ID | 68575 |
| SCHEMBL ID | 48098 |
| MeSH ID | M0498679 |
| Synonym |
|---|
| HY-14299 |
| indacaterol |
| 312753-06-3 |
| 753498-25-8 |
| indacaterol (usan/inn) |
| D09318 |
| 5-[(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-2(1h)-quinolinone maleic acid |
| qab149 |
| chebi:68575 , |
| CHEMBL1095777 , |
| onbrez |
| qab-149 |
| indacterol |
| bdbm50318159 |
| 8-hydroxy-5-[(r)-1-hydroxy-2-(5,6-diethylindan-2-ylamino)-ethyl]-1h-quinolin-2-one |
| 5-[(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one |
| 5-{(1r)-2-((5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino)-1-hydroxyethyl}-8-hydroxyquinolin-2(1h)-one |
| unii-8or09251mq |
| arcapta |
| qab 149 |
| 8or09251mq , |
| indacaterol [usan:inn:ban] |
| 5-(2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1h-quinolin-2-one |
| BCP9000787 |
| BCP0726000140 |
| indacaterol [vandf] |
| indacaterol [inn] |
| indacaterol [who-dd] |
| indacaterol [usan] |
| indacaterol [mi] |
| indacaterol [mart.] |
| CS-0744 |
| 5-{(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1h)-one |
| 5-[(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one; qab 149 |
| S5654 |
| DB05039 |
| SCHEMBL48098 |
| (r)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one |
| 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1h-quinolin-2-one |
| QZZUEBNBZAPZLX-QFIPXVFZSA-N |
| gtpl7455 |
| AC-27668 |
| AKOS024463516 |
| (r)-5-(2-(5,6-diethyl-2,3-dihydro-1h-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one |
| AB01565805_02 |
| 5-[(1r)-2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one |
| J-521526 |
| DTXSID90185198 |
| mfcd18782702 |
| BCP03766 |
| Q425654 |
| (r)-5-[2-[(5,6-diethyl-2,3-dihydro-1h-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one |
| HMS3886I14 |
| 312753-06-3 (free base) |
| CCG-268560 |
| NCGC00386216-07 |
| A855441 |
| AS-56318 |
| benzyl hydrogen (3-{[(2r,3s)-2-{(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)-4-morpholinyl]methyl}-5-oxo-2,5-dihydro-1h-1,2,4-triazol-1-yl)phosphonate |
| A900064 |
| EX-A6067 |
| EN300-20321622 |
Indacaterol is an ultra-long-acting β2-adrenoceptor agonist that is indicated for the maintenance treatment of chronic obstructive pulmonary disease. It is a novel addition to existing long-acting bronchodilators.
Indacaterol has a 24-hour bronchodilatory effect, which allows for once-daily administration. The drug is appropriate for the maintenance treatment of patients with COPD.
Indacaterol maleate has been developed as a new once-daily inhaled beta(2)-selective agonist. The drug has been approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Indacaterol has a 24-hour bronchodilatory effect, which allows for once-daily administration." | ( Indacaterol: in chronic obstructive pulmonary disease. Moen, MD, 2010) | 2.52 |
| "Indacaterol has a good profile of safety and tolerability that is appropriate for the maintenance treatment of patients with COPD." | ( Safety of indacaterol in the treatment of patients with COPD. Donohue, JF; Kornmann, O; Kramer, B; Lassen, C; Lawrence, D; Singh, D, 2011) | 2.21 |
| "Indacaterol has a fast onset of action after the first dose and is effective over 24 hours, allowing for once-daily administration." | ( Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. McKeage, K, 2012) | 2.54 |
| "Indacaterol studies have shown significant improvements in lung function of COPD patients, and these improvements have also translated into clinically meaningful improvements in patient symptoms and HR-QOL." | ( Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol. Feldman, GJ, 2013) | 1.33 |
| "Indacaterol maleate has been developed as a new once-daily inhaled beta(2)-selective agonist." | ( Indacaterol maleate for the treatment of chronic obstructive pulmonary disease. Tashkin, DP, 2010) | 2.52 |
| "Indacaterol has been shown to provide effective 24-h bronchodilation and a fast onset of action, with an efficacy at least comparable or superior to current bronchodilator therapy standards and with a favourable safety and tolerability profile within the β(2)-agonist drug class." | ( An update on the use of indacaterol in patients with COPD. Amor-Carro, O; Brienza, NS; Ramos-Barbón, D, 2011) | 1.4 |
| "Indacaterol has been recently approved in Europe for the treatment of chronic obstructive pulmonary disease (COPD). " | ( Validation of an on-line solid-phase extraction method coupled to liquid chromatography-tandem mass spectrometry detection for the determination of Indacaterol in human serum. Agarwal, A; Bonvie, A; Chaturvedi, A; Deglave, F; Emotte, C; Heudi, O; Kretz, O; Majumdar, T; Masson, L; Picard, F; Woessner, R, 2012) | 2.02 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Indacaterol seemed to cause more adverse events than placebo only at a dose of 600 μg daily and a duration of 52 weeks (risk ratio 1.15; 95 % CI, 1.04, 1.26)." | ( Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Jiang, FM; Li, CT; Liang, ZA; Luo, J; Wang, RC; Zheng, QL, 2013) | 1.38 |
Indacaterol treatment was accompanied by significant reductions in COPD exacerbations. Patients had greater improvements in transition dyspnoea index (TDI) and St George's Respiratory Questionnaire (SGRQ) total score.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Indacaterol treatment was accompanied by significant reductions in COPD exacerbations (rate ratios compared with placebo, 0.62-0.64; P < .05) and as-needed albuterol use (1.2-1.4 puffs/d decrease, P < .001 compared with placebo)." | ( Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chapman, KR; Dogra, A; Kramer, B; Lassen, C; Owen, R; Rennard, SI, 2011) | 1.37 |
| "Indacaterol-treated patients had greater improvements in transition dyspnoea index (TDI) total score (least squares means 2.01 versus 1.43; p<0.001) and St George's Respiratory Questionnaire (SGRQ) total score (least squares means 37.1 versus 39.2; p<0.001; raw mean change from baseline -5.1 versus -3.0), and were significantly more likely to achieve clinically relevant improvements in these end-points (indacaterol versus tiotropium odds ratios of 1.49 for TDI and 1.43 for SGRQ, both p<0.001)." | ( Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Amos, C; Buhl, R; Disdier, C; Dunn, LJ; Henley, M; Kramer, B; Lassen, C, 2011) | 1.36 |
| "Treatment with indacaterol/glycopyrronium 85/43 mcg every 24 hours for 3 months improved diaphragmatic mobility in patients with COPD with moderate to very severe airway obstruction. " | ( Ultrasound assessment of diaphragmatic dynamics in patients with chronic obstructive pulmonary disease after treatment with indacaterol/glycopyrronium. Figueira-Gonçalves, JM; Golpe, R; Guanche-Dorta, S; Ramallo-Fariña, Y; Wangüemert-Pérez, AL, 2023) | 1.47 |
| "Treatment with indacaterol in addition to a long-acting muscarinic antagonist was also useful." | ( Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences. Hanada, S; Muraki, M; Ohno, T; Sawaguchi, H; Tohda, Y; Wada, S, 2014) | 1.12 |
| "Treatment with indacaterol 75 μg may provide useful improvements in patient-reported outcomes in patients with moderate-to-severe COPD." | ( Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. Gotfried, MH; Kerwin, EM; Kramer, B; Lassen, C; Lawrence, D, 2012) | 1.1 |
| "Treatment with indacaterol 75 µg once daily provides effective bronchodilation, improves dyspnea and health status, and has a well characterized profile of safety and tolerability." | ( Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective. Kerwin, EM; Williams, J, 2013) | 2.17 |
Commonest adverse events with indacaterol were COPD worsening, nasopharyngitis, and headache. Most cases were mild or moderate and incidence was generally similar to placebo and other active treatments.
In the all-Asian study, indacaterol serum concentration-time pharmacokinetic profiles in Japanese patients (n = 102) were similar to those in the overall population. No ethnicity effect was observed when compared with the overall Asian patient population or with the Caucasian patient population. In both populations, the average maximum serum concentration (Cmax) was observed at the first sampling time point.
| Excerpt | Reference | Relevance |
|---|---|---|
| "No more effective than tiotropium combined with formoterol." | ( Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD. , 2014) | 0.74 |
| "The ability of a chronic treatment with indacaterol, a new ultra-long-acting β2 -adrenoceptor agonist, to reverse cardiac remodelling and its effects in combination with metoprolol, a selective β1 -adrenoceptor antagonist, were investigated on myocardial infarction in a rat model of heart failure (HF)." | ( Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. Calzetta, L; Capuano, A; Donniacuo, M; Gritti, G; Martuscelli, E; Matera, MG; Orlandi, A; Rafaniello, C; Rinaldi, B; Rossi, F; Sodano, L, 2015) | 0.91 |
Indacaterol is an inhaled, ultra-long-acting β2-agonist that provides 24-h bronchodilation with once-daily dosing in patients with chronic obstructive pulmonary disorder. The OD dosing makes indacaterOL more convenient for COPD patients and is likely to positively influence the patient's adherence.
| Role | Description |
|---|---|
| beta-adrenergic agonist | An agent that selectively binds to and activates beta-adrenergic receptors. |
| bronchodilator agent | An agent that causes an increase in the expansion of a bronchus or bronchial tubes. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| quinolone | |
| monohydroxyquinoline | A hydroxyquinoline carrying a single hydroxy substituent. |
| indanes | |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | Ki | 0.0391 | 0.0000 | 0.6635 | 9.5499 | AID1185817; AID481516; AID501435 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 (µMol) | 0.3162 | 0.0002 | 1.4681 | 9.0000 | AID643244 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | Ki | 0.0912 | 0.0001 | 1.3391 | 9.9840 | AID1185818; AID501436 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 1.0480 | 0.0000 | 0.6020 | 10.0000 | AID1185819 |
| Cytochrome P450 1B1 | Homo sapiens (human) | IC50 (µMol) | 59.2000 | 0.0013 | 0.8696 | 9.9000 | AID1737231 |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | IC50 (µMol) | 0.0079 | 0.0004 | 0.1680 | 0.9772 | AID1185820 |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0760 | 0.0004 | 0.5902 | 2.5119 | AID481516 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | EC50 (µMol) | 0.0073 | 0.0000 | 0.3111 | 10.0000 | AID1185823; AID1760531; AID481517; AID643219 |
| D(2) dopamine receptor | Homo sapiens (human) | EC50 (µMol) | 10.0000 | 0.0000 | 0.1874 | 3.9000 | AID1185826 |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | EC50 (µMol) | 0.0110 | 0.0002 | 0.8843 | 8.2000 | AID481517 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID481525 | Inhibition of serotonin-induced bronchoconstriction in guinea pig assessed as intrinsic duration of bronchodilatory activity at ED80 | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID1458066 | Binding affinity to POPC liposome membrane at compound to POPC molar ratio of 1:10 after 3 milliseconds in presence of Mn2+ by 2D NOESY NMR analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID1222793 | Dissociation constant, pKa of the compound | 2013 | Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5 | Which metabolites circulate? |
| AID1185827 | Thermodynamic solubility of the compound at pH 6.8 | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1185834 | Inhibition of methacholine-induced bronchoconstriction in rhesus monkey administered through inhalation 5 mins prior challenge | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1185823 | Agonist activity at adrenergic beta2 receptor in human A431 cells assessed as elevation of cAMP level | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1760531 | Agonist activity at beta2 adrenoceptor (unknown origin) | 2020 | Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24 | Recent Advances in β |
| AID1185830 | Protein binding in human plasma by ultrafiltration method | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1851155 | Inhibition of SRSF6 (unknown origin) | 2022 | Bioorganic & medicinal chemistry, 09-15, Volume: 70 | A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing. |
| AID1458048 | Binding affinity to POPC liposome membrane assessed as cross-relaxation rate of E proton with C-3/C-2 region of lipid at compound to POPC molar ratio of 1:10 by NOESY 1H NMR analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID1137785 | Agonist activity at beta-2 adrenergic receptor in guinea pig tracheal rings assessed as time required to reach 90% of final relaxation of methacholine-constricted tracheal rings | 2014 | ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4 | Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action. |
| AID1458045 | Binding affinity to POPC liposome membrane assessed as 31P chemical shift anisotropy at compound to POPC molar ratio of 1:10 by NMR analysis (Rvb = 28.9 ppm) | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID1185829 | Lipophilicity, logK of the compound immobilised on artificial membrane by chromatographic method | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID481520 | Agonist activity at beta2 adrenergic receptor in guinea pig tracheal strip assessed as time required to reach maximal inhibition of electrically-induced bronchoconstriction | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID1458057 | n-octanol/PBS/sodium carbonate partition coefficient, log P of the compound after 4 hrs | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID1185820 | Agonist activity at adrenergic beta2 receptor in electrically-stimulated Dunkin-Hartley guinea pig tracheal strip assessed as inhibition of contraction | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1458058 | Binding affinity to POPC liposome membrane at compound to POPC molar ratio of 1:10 after 3 milliseconds by 2D NOESY NMR analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID643245 | Selectivity ratio of pIC50 for beta1 adrenoceptor to pEC50 for human beta2 adrenoceptor | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. |
| AID481517 | Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID481518 | Agonist activity at human beta2 adrenergic receptor assessed as increase in cAMP level by whole cell assay relative to formoterol | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID1137784 | Agonist activity at beta-2 adrenergic receptor in human bronchial rings assessed as time required to reach 90% of final relaxation of carbachol-constricted bronchial rings | 2014 | ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4 | Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action. |
| AID1185826 | Activity at human D2R expressed in CHO cells by radiolabelled [35S]GTPgammaS assay | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID481514 | Plasma protein binding in human at 1 to 2000 ng/mL after 3 hrs by liquid scintillation counting | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID1760530 | Agonist activity at beta1 adrenoceptor in electrically stimulated Dunkin Hartley guinea pig left atria assessed as induction of isoprenaline-induced contraction incubated for 10 to 15 mins by alphascreen technology | 2020 | Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24 | Recent Advances in β |
| AID1760549 | Inhibition of acetylcholine-induced bronchoconstriction in guinea pig assessed as duration of action by measuring half life | 2020 | Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24 | Recent Advances in β |
| AID1185832 | Clearance in rat at 5 umol/kg, iv | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1737231 | Inhibition of human CYP1B1 using 7-ethyl-O-resorufin as substrate incubated for 30 mins in presence of NADPH by EROD assay | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. |
| AID1737234 | Inhibition of human CYP1B1 at 5 uM using 7-ethyl-O-resorufin as substrate incubated for 30 mins in presence of NADPH by EROD assay | 2020 | European journal of medicinal chemistry, May-01, Volume: 193 | Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. |
| AID1458060 | Binding affinity to POPC liposome membrane in liquid disorder phase assessed as broadening of POPC signals at compound to POPC molar ratio of 1:5 by 1D 1H Mass spectra analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID481523 | Intrinsic clearance in rat liver microsomes assessed per mg of protein at 1 uM after 10 to 30 mins by LC/MS analysis in presence of NADPH | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID1137783 | Intrinsic activity at beta-2 adrenergic receptor in guinea pig tracheal rings | 2014 | ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4 | Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action. |
| AID501435 | Displacement of [3H]CGP12177 from human beta2 adrenoceptor | 2010 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17 | A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. |
| AID1185819 | Displacement of [125I]7-HO-PIPAT from human D3R expressed in HEK cells | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1458056 | Binding affinity to POPC liposome membrane in liquid disorder phase assessed as change in cross-relaxation rate of lypophilic group E protons with C2/C3 segment at compound to POPC molar ratio of 1:10 to 1:5 by 1D 1H Mass spectra analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID481512 | Chromatographic hydrophobicity index at 2 mg/ml at pH 7.4 by rapid gradient HPLC analysis | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID643246 | Drug metabolism in rat hepatocytes | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. |
| AID1458055 | Binding affinity to POPC liposome membrane in liquid disorder phase assessed as change in cross-relaxation rate of hydrophilic group B protons with G-3 segment at compound to POPC molar ratio of 1:10 to 1:5 by 1D 1H Mass spectra analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID1185817 | Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta2 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID481519 | Agonist activity at beta2 adrenergic receptor in guinea pig tracheal strip assessed as inhibition of electrically-induced bronchocontractile response after 30 mins | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID1185825 | Agonist activity at adrenergic beta1 receptor in guinea-pig left atria assessed as inhibition of electrically-stimulated contraction | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID643219 | Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. |
| AID1185818 | Displacement of [125I]iodo-(+/-)-cyanopindolol from human adrenergic beta1 receptor expressed in CHO cells after 3 hrs by radio-ligand binding assay | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID481515 | Fraction unbound in human plasma | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID481521 | Agonist activity at beta2 adrenergic receptor in guinea pig tracheal strip assessed as duration of maximal inhibitory action against electrically-induced bronchoconstriction | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID1137786 | Agonist activity at beta-2 adrenergic receptor in guinea pig tracheal rings assessed as relaxation of methacholine-constricted tracheal rings | 2014 | ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4 | Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action. |
| AID1137782 | Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as accumulation of intracellular cAMP | 2014 | ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4 | Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action. |
| AID643244 | Binding affinity to beta1 adrenoceptor | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. |
| AID481524 | Intrinsic clearance in rat liver microsomes assessed per mg of protein at 1 uM after 10 to 30 mins by LC/MS analysis in presence of UDP-glucuronic acid | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID643235 | Bronchoprotective activity in it dosed guinea pig assessed as inhibition of histamine-induced constriction | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. |
| AID501436 | Displacement of [3H]CGP12177 from human beta-1 adrenoceptor | 2010 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17 | A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. |
| AID1185843 | Volume of distribution at steady state in rat at 5 umol/kg, iv | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1458054 | Binding affinity to POPC liposome membrane in liquid disorder phase assessed as change in cross-relaxation rate of hydrophilic group B protons with G-1 segment at compound to POPC molar ratio of 1:10 to 1:5 by 1D 1H Mass spectra analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID643243 | 1-Octanol-aqueous buffer distribution coefficient, log D at pH 7.4 by LC/MS analysis | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. |
| AID481516 | Displacement of [125I]cyanopindolol from human recombinant beta2 adrenergic receptor expressed in CHO cells by filtration assay | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID481513 | Binding affinity to human serum albumin by UV/HPLC analysis | 2010 | Journal of medicinal chemistry, May-13, Volume: 53, Issue:9 | The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. |
| AID1185828 | Lipophilicity, logD of the compound at pH 7.4 by chromatographic method | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1458046 | Binding affinity to POPC liposome membrane assessed as 31P chemical shift anisotropy at compound to POPC molar ratio of 1:10 in presence of Mn2+ by NMR analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID1458059 | Lipophilicity of the compound assessed as capacity factor (CHI IAM7.4) at pH 7.4 by chromatographic analysis | 2017 | Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16 | Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. |
| AID643220 | Agonist activity at human beta2 adrenoceptor expressed in H292 cells assessed as increase in cAMP accumulation after 60 mins by spectrophotometry relative to formoterol | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. |
| AID1185821 | Agonist activity at adrenergic beta2 receptor in electrically-stimulated Dunkin-Hartley guinea pig tracheal strip assessed as time to maximal effect at IC50 | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID643231 | Terminal half life in iv dosed rat | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1 | From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. |
| AID1185822 | Agonist activity at adrenergic beta2 receptor in electrically-stimulated Dunkin-Hartley guinea pig tracheal strip assessed as time for response to fall to 50% of maximal response during washout phase at IC50 | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1185824 | Agonist activity at adrenergic beta2 receptor in human A431 cells assessed as elevation of cAMP level relative to formoterol | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17 | The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. |
| AID1346250 | Human beta2-adrenoceptor (Adrenoceptors) | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol. |
| AID1346260 | Human beta1-adrenoceptor (Adrenoceptors) | 2012 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19 | An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (7.19) | 29.6817 |
| 2010's | 240 (82.19) | 24.3611 |
| 2020's | 31 (10.62) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (67.45) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 101 (32.69%) | 5.53% |
| Reviews | 79 (25.57%) | 6.00% |
| Case Studies | 6 (1.94%) | 4.05% |
| Observational | 4 (1.29%) | 0.25% |
| Other | 119 (38.51%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||